{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:01:24Z","timestamp":1785769284522,"version":"3.56.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychoneuroendocrinology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.psyneuen.2014.12.012","type":"journal-article","created":{"date-parts":[[2014,12,20]],"date-time":"2014-12-20T11:01:38Z","timestamp":1419073298000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms"],"prefix":"10.1016","volume":"53","author":[{"given":"Yi-Ling","family":"Chien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Chi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming H.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Gwo","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5356-940X","authenticated-orcid":false,"given":"Lih-Chu","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psyneuen.2014.12.012_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1113\/jphysiol.2008.164400","article-title":"The hypocretins as sensors for metabolism and arousal","volume":"587","author":"Adamantidis","year":"2009","journal-title":"J. Physiol."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.npep.2004.06.004","article-title":"Stereological analysis of the hypothalamic hypocretin\/orexin neurons in an animal model of depression","volume":"38","author":"Allard","year":"2004","journal-title":"Neuropeptides"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/YPG.0b013e328341a3db","article-title":"Panic disorder is associated with the Val308Iso polymorphism in the hypocretin receptor gene","volume":"21","author":"Annerbrink","year":"2011","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/0269881105058978","article-title":"Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic","volume":"19","author":"Ascher-Svanum","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000342345","article-title":"Negative symptoms and executive function in schizophrenia: does their relationship change with illness duration?","volume":"46","author":"Bagney","year":"2013","journal-title":"Psychopathology"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0035","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.neuron.2005.05.016","article-title":"Hypocretins: waking, arousal, or action?","volume":"46","author":"Berridge","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0040","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/ncomms2461","article-title":"Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction","volume":"4","author":"Blouin","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0045","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.euroneuro.2007.01.005","article-title":"Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder","volume":"17","author":"Brundin","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jad.2008.04.011","article-title":"Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt","volume":"113","author":"Brundin","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jad.2006.10.019","article-title":"Orexin and psychiatric symptoms in suicide attempters","volume":"100","author":"Brundin","year":"2007","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0060","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/sj.mp.4001363","article-title":"Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects","volume":"8","author":"Dalal","year":"2003","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0065","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0070","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/schbul\/sbm096","article-title":"The orexins\/hypocretins and schizophrenia","volume":"33","author":"Deutch","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0075","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.regpep.2004.02.004","article-title":"Pharmacokinetic profile of orexin A and effects on plasma insulin and glucagon in the rat","volume":"119","author":"Ehrstrom","year":"2004","journal-title":"Regul. Pept."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0920-9964(02)00302-X","article-title":"The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis","volume":"61","author":"Emsley","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0085","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1523\/JNEUROSCI.22-15-06742.2002","article-title":"Differential activation of orexin neurons by antipsychotic drugs associated with weight gain","volume":"22","author":"Fadel","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0090","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.brainres.2009.08.046","article-title":"Orexin\/hypocretin modulation of the basal forebrain cholinergic system: role in attention","volume":"1314","author":"Fadel","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0095","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/schbul\/23.3.437","article-title":"Functional and anatomical aspects of prefrontal pathology in schizophrenia","volume":"23","author":"Goldman-Rakic","year":"1997","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00213-003-1438-6","article-title":"Involvement of the prefrontal cortex but not the dorsal hippocampus in the attention-enhancing effects of nicotine in rats","volume":"168","author":"Hahn","year":"2003","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.tins.2006.08.002","article-title":"Arousal and reward: a dichotomy in orexin function","volume":"29","author":"Harris","year":"2006","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0110","series-title":"The Wisconsin Card Sorting Test Manual","author":"Heaton","year":"1981"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0115","series-title":"Wisconsin Card Sorting Test (WCST). Manual Revised and Expanded","author":"Heaton","year":"1993"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0120","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1210\/en.2011-1652","article-title":"Orexins\/hypocretins act in the posterior paraventricular thalamic nucleus during repeated stress to regulate facilitation to novel stress","volume":"152","author":"Heydendael","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0125","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1176\/ajp.2006.163.12.2184","article-title":"Impact of modafinil on prefrontal executive function in schizophrenia","volume":"163","author":"Hunter","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0920-9964(01)00251-1","article-title":"Symptom patterns and subgrouping of schizophrenic patients: significance of negative symptoms assessed on admission","volume":"56","author":"Hwu","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0135","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.neuroscience.2008.09.042","article-title":"I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation","volume":"157","author":"Ito","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nm.2075","article-title":"A key role for orexin in panic anxiety","volume":"16","author":"Johnson","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0150","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1037\/0894-4105.12.2.289","article-title":"Factor structure of the Wisconsin Card Sorting Test: dimensions of deficit in schizophrenia","volume":"12","author":"Koren","year":"1998","journal-title":"Neuropsychology"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0155","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1152\/ajpcell.00227.2012","article-title":"Physiology of the orexinergic\/hypocretinergic system: a revisit in 2012","volume":"304","author":"Kukkonen","year":"2013","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0160","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.neubiorev.2005.02.006","article-title":"Nicotine use in schizophrenia: the self medication hypotheses","volume":"29","author":"Kumari","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0165","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1523\/JNEUROSCI.0719-05.2005","article-title":"Hypocretin and nicotine excite the same thalamocortical synapses in prefrontal cortex: correlation with improved attention in rat","volume":"25","author":"Lambe","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1076\/1380-3395(200002)22:1;1-8;FT069","article-title":"Performance on the Wisconsin Card Sorting Test among adolescents in Taiwan: norms, factorial structure, and relation to schizotypy","volume":"22","author":"Lin","year":"2000","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0175","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/schbul\/sbs141","article-title":"Performance on the Wisconsin Card Sorting Test in families of schizophrenia patients with different familial loadings","volume":"39","author":"Lin","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0180","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1523\/JNEUROSCI.5584-07.2008","article-title":"Orexin signaling mediates the antidepressant-like effect of calorie restriction","volume":"28","author":"Lutter","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0185","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ajmg.b.30330","article-title":"Neurocognitive deficits in first-episode schizophrenic patients and their first-degree relatives","volume":"144B","author":"Ma","year":"2007","journal-title":"Am. J. Med. Genet. B: Neuropsychiatr. Genet."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0190","doi-asserted-by":"crossref","first-page":"118","DOI":"10.47102\/annals-acadmedsg.V39N2p118","article-title":"Weight gain in Asian patients on second-generation antipsychotics","volume":"39","author":"Mahendran","year":"2010","journal-title":"Ann. Acad. Med. Singap."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0195","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.biopsych.2005.04.015","article-title":"Association of an orexin 1 receptor 408Val variant with polydipsia-hyponatremia in schizophrenic subjects","volume":"58","author":"Meerabux","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-9964(01)00326-7","article-title":"Clozapine-induced weight gain predicts improvement in psychopathology","volume":"59","author":"Meltzer","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0205","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/j.1471-4159.1990.tb01230.x","article-title":"Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study","volume":"54","author":"Moghaddam","year":"1990","journal-title":"J. Neurochem."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0210","series-title":"Annual meeting of Society for Neuroscience, Program # 839.8 Abstract CD","article-title":"The effects of selective orexinergic deafferentation in the medial, prefrontal cortex on sustained attention","author":"Newman","year":"2007"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(02)00032-X","article-title":"CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture","volume":"110","author":"Nishino","year":"2002","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0220","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neuroscience.2012.05.033","article-title":"The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus","volume":"218","author":"Nocjar","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0225","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/385634a0","article-title":"Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET","volume":"385","author":"Okubo","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0230","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0920-9964(98)00156-X","article-title":"Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage","volume":"37","author":"Pantelis","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0235","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/arclin\/10.5.463","article-title":"Construct validity of the WCST in normal elderly and persons with Parkinson's disease","volume":"10","author":"Paolo","year":"1995","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0240","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neulet.2010.02.062","article-title":"CSF hypocretin-1 concentrations correlate with the level of fatigue in multiple sclerosis patients","volume":"474","author":"Papuc","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0245","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.brainresbull.2008.09.014","article-title":"Activation of orexin\/hypocretin projections to basal forebrain and paraventricular thalamus by acute nicotine","volume":"77","author":"Pasumarthi","year":"2008","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0250","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"Peyron","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0255","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4088\/JCP.v68n0507","article-title":"A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia","volume":"68","author":"Pierre","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0260","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1523\/JNEUROSCI.5724-09.2010","article-title":"Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior","volume":"30","author":"Plaza-Zabala","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0265","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jad.2010.10.033","article-title":"Association between major mood disorders and the hypocretin receptor 1 gene","volume":"130","author":"Rainero","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0270","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/schbul\/sbm087","article-title":"The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms","volume":"33","author":"Rasmussen","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0275","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/sj.npp.1301239","article-title":"The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy","volume":"32","author":"Rasmussen","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0280","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jad.2010.12.004","article-title":"Orexin expression and promoter-methylation in peripheral blood of patients suffering from major depressive disorder","volume":"131","author":"Rotter","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0290","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.schres.2012.11.026","article-title":"Executive functioning in schizophrenia spectrum disorder patients and their unaffected siblings: a ten-year follow-up study","volume":"143","author":"Sanchez-Torres","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0295","doi-asserted-by":"crossref","first-page":"839","DOI":"10.4088\/JCP.v66n0705","article-title":"Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications","volume":"66","author":"Sevy","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0300","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.npp.1300881","article-title":"Effects of nicotine nasal spray on cognitive function in schizophrenia","volume":"31","author":"Smith","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0305","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.yhbeh.2013.12.014","article-title":"The orexin-1 receptor antagonist SB-334867 attenuates anxiety in rats exposed to cat odor but not the elevated plus maze: an investigation of Trial 1 and Trial 2 effects","volume":"65","author":"Staples","year":"2014","journal-title":"Horm. Behav."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0310","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.psyneuen.2010.01.001","article-title":"Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder","volume":"35","author":"Strawn","year":"2010","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0315","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/sj.npp.1300457","article-title":"Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia","volume":"29","author":"Turner","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0320","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbr.2013.12.045","article-title":"The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy","volume":"262","author":"Weinhold","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0325","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1358\/dnp.2003.16.8.829349","article-title":"The role of the hypocretinergic system in the integration of networks that dictate the states of arousal","volume":"16","author":"Winsky-Sommerer","year":"2003","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0330","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4088\/JCP.v60n0602","article-title":"Novel antipsychotics: comparison of weight gain liabilities","volume":"60","author":"Wirshing","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2014.12.012_bib0335","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnins.2014.00036","article-title":"Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls","volume":"8","author":"Yeoh","year":"2014","journal-title":"Front. Neurosci."}],"container-title":["Psychoneuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453014004661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453014004661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T16:47:35Z","timestamp":1759682855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306453014004661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":67,"alternative-id":["S0306453014004661"],"URL":"https:\/\/doi.org\/10.1016\/j.psyneuen.2014.12.012","relation":{},"ISSN":["0306-4530"],"issn-type":[{"value":"0306-4530","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms","name":"articletitle","label":"Article Title"},{"value":"Psychoneuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psyneuen.2014.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}